VOR - Stock Analysis & Overview

About Vor Biopharma Inc.

Biotechnology

Healthcare

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Vor Biopharma Inc. Key Metrics

Market Cap: $65M
52 Weeks Low: $0.70
52 Weeks High: $3.14
P/B: 0.66x
P/E: -0.55x
P/S: 5.34x

Upcoming Events

VOR Analyst Forecasts

‌

VOR Financials

VOR Income Statement Key Metrics

Revenue(TTM)12.23 M
Gross Profit(TTM)7.40 M
EBITDA(TTM)-122.07 M
Net Income(TTM)-118.09 M
EPS Diluted(TTM)-1.74

Decode VOR's Latest Earnings Call with Ease

Tap 'Generate' for a crystal-clear,
AI-crafted summary and stay ahead in the investment game!

VOR earnings and revenue history

VOR Return on Equity

See how efficiently VOR generates profit for it's shareholders.

-78.20%

100

Poor

Average

Strong

Return on Equity vs Peers

Return on Equity ratio of VOR (-0.782) is lower than the average of its peers (-0.425).

Return on Equity Growth

VOR's Return on Equity has shown poor growth over the past 10 years, increasing by only -4.13%.

VOR Revenue Growth

See how VOR has grown it's revenue over the past 10 years.

‌

Revenue Growth

VOR's revenue has shown poor growth over the past 10 years, increasing by only 0%.

Vor Biopharma Inc.

Page title

Section title